Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.21 USD | -4.37% | +5.53% | +8.87% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 845M |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -166M | EV / Sales 2024 * | - |
Net Debt 2024 * | 952K | Net Debt 2025 * | 13.89M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.57
x | P/E ratio 2025 * |
-5.62
x | Employees | 72 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.67% |
Latest transcript on ALX Oncology Holdings Inc.
1 day | -4.37% | ||
1 week | +5.53% | ||
Current month | -4.76% | ||
1 month | +21.15% | ||
3 months | +15.29% | ||
6 months | +107.82% | ||
Current year | +8.87% |
Managers | Title | Age | Since |
---|---|---|---|
Jaume Pons
FOU | Founder | 58 | 15-03-31 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Peter García
DFI | Director of Finance/CFO | 62 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 22-11-27 |
Corey Goodman
CHM | Chairman | 72 | 15-02-28 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +9.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 16.21 | -4.37% | 388,639 |
24-05-09 | 16.95 | +2.05% | 360,288 |
24-05-08 | 16.61 | -5.41% | 471,166 |
24-05-07 | 17.56 | +11.28% | 950,245 |
24-05-06 | 15.78 | +2.73% | 976,158 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.87% | 845M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ALXO Stock